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Abstract: Melatonin (N-acetyl-5-methoxytryptamine) has been discovered as a hormone 
secreted by the pineal gland, even though it is also synthetized in various other organs, tissues, 
and cells. The circadian rhythm of melatonin is often used as an indicator phase position since it 
is a well-defined, high-amplitude rhythm controlled by the hypothalamic suprachiasmatic nuclei. 
Melatonin production is controlled by this endogenous circadian timing system. It peaks during 
the night and is suppressed by daylight. Mood spectrum disorders, including bipolar disorder 
(BD), major depressive disorder (MDD), and seasonal affective disorder (SAD), have been 
observed to be accompanied by circadian dysregulation as well as dysregulation in melatonin 
secretion. Simultaneously, it has also been documented that disruptions in circadian rhythms, 
including the sleep/wake cycle, though environmental means can produce mood-related prob-
lems in vulnerable individuals. These findings suggested that altered circadian rhythms might be 
biological markers of these disorders. As melatonin is considered a chronobiotic factor, ie, able 
to entrain the circadian rhythms of several biological functions (eg, activity/rest, sleep/wake, 
body temperature, endocrine rhythms, etc), its use may provide a new therapeutic approach 
for the treatment of affective disorders. However, the available evidence is controversial. This 
review summarizes the data published so far about reliable evidence on the role of melatonin 
in affective disorders.
Keywords: melatonin, melatonergic system, mood disorders, depression, seasonal affective 
disorder, bipolar disorder
Introduction
Melatonin (chemically, N-acetyl-5-methoxytryptamine) is an indolamine hormone 
isolated and characterized, in 1958, by the dermatologist Aaron Lerner who found, in 
extracts of bovine pineal glands, an amphibian skin-lighting factor, subsequently called 
melatonin due to its ability of inducing contraction of stellate amphibian  melanophores.1 
It is mainly synthetized, as a derivative of the amino acid tryptophan, by the parenchymal 
cells of the pineal gland,2 and then rapidly secreted into the blood vascular system and 
cerebrospinal fluid. Secondary sources are retina, gut, skin, platelets, bone marrow, 
and other structures.3–8 The synthesis involves three enzymatic steps. The first is the 
metabolization of l-tryptophan to serotonin (or 5-hydroxytryptamine). The second 
step is the N-acetylation by the enzyme serotonin N-acetyltransferase (SNAT) to yield 
N-acetylserotonin. The physiological regulation of SNAT, with its sharp increase in 
activity at night, is considered the major regulatory step in melatonin synthesis.9,10 
The final step of the synthesis pathway is the conversion of N-acetylserotonin to 
melatonin by the action of the enzyme hydroxyindole-O-methyltransferase (HIOMT). 
 
Ch
ro
no
Ph
ys
io
lo
gy
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
1.
97
.2
1.
39
 o
n 
20
-M
ar
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
ChronoPhysiology and Therapy 2015:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
66
De Berardis et al
The day/night changes of HIOMT are less prominent; 
however, HIOMT gene transcription has also been described 
to have a day/night rhythm.11
Melatonin is secreted by the pineal gland by simple 
 diffusion. Its lipophilicity contributes to its easy passive dif-
fusion across cell membranes as well as through cell  layers.12 
About 60%–70% of melatonin in the plasma is bound to 
albumin.13,14 Its plasma half-life after intravenous infusion is 
about 30 minutes,15 but a biphasic elimination pattern with 
half-lives of about 3 and 45 minutes has also been observed 
following oral administration.16 The circulating melatonin is 
rapidly converted to 6-hydroxymelatonin in the liver, which 
clears 92%–97% of circulating melatonin in a single pass. 
The 6-hydroxymelatonin is then conjugated and excreted in 
urine. The sulfate derivative of 6-hydroxymelatonin accounts 
for 50%–80% of the excreted melatonin and the glucuronide 
derivative for 5%–30%. The remaining melatonin is excreted 
either unchanged (less than 1%), as 5-methoxyindoleacetic 
acid (0.5%), or as the nonindolic metabolite N-acetyl-5-
methoxykynurenamine (15%).17,18
The rhythm of melatonin synthesis and secretion is 
entrained to a circadian period largely by the environmental 
alteration of light and darkness.19 Light is perceived by a sub-
type of retinal ganglion cells, which transmits photic stimuli 
to the suprachiasmatic nucleus (SCN) of the hypothalamus 
through the retino-hypothalamic tract.20–22 The SCN, in turn, 
conveys the signal to the pineal gland through a multisyn-
aptic pathway and is responsible of the circadian rhythm of 
melatonin, which is characterized by a gradual rise suddenly 
after the time of lights off and by a peak at the middle of 
the night (around 03:00–04:00 am), with a subsequent slow 
decline during the second part of the night.19 This remark-
able diurnal variation is also determined by the secretion 
of norepinephrine, released at night from postganglionic 
sympathetic nerves that innervate the pineal gland. The 
stimulation of the sympathetic nerves on the pineal gland is 
strictly connected to the environmental light–dark cycle.2,13 
Furthermore, melatonin synthesis depends upon tryptophan 
availability23 and other nutritional factors such as folate status 
and vitamin B
6
, a coenzyme in tryptophan decarboxylation 
which is able to stimulate melatonin production.24–26
Melatonin acts through the activation of specific recep-
tors which are called MT1 and MT2.27 They belong to the 
superfamily of seven-transmembrane superfamily G protein-
coupled receptors. Their activation leads to the inhibition of 
the adenylate cyclase with subsequent decrease of intracel-
lular cyclic adenosine monophosphate which, in turn, pro-
vokes the inhibition of protein kinase A and of CREB protein 
phosphorylation.28,29 MT2 receptor additionally inhibits the 
soluble guanylyl cyclase pathway.30,31 However, depending 
on the tissue and species, melatonin receptor activation can 
elicit a variety of second messenger cascades.27 In fact, MT1 
and MT2 were also found in many other tissues (eg, retina, 
ovary, testis, mammary gland, liver, kidney, skin, immune 
system, duodenum, adipocytes, myometrium, etc).3–8
Melatonin levels can be assessed by measuring its levels 
in blood, saliva, and by measuring its urinary metabolite, the 
6-sulfatoxymelatonin (aMT6s). The most commonly used 
circadian melatonin phase marker is the dim light melatonin 
onset (DLMO).32 DLMO marks the time of the beginning 
of one’s biological night and is also useful for assessing 
circadian misalignment and for phase typing. It is defined 
as the interpolated clock time at which the ascending phase 
of melatonin reaches 20 pg/mL. Some authors use a cut-off 
of a smaller value, such as 10 pg/mL or even lower.33 The 
phase angle difference (PAD) between DLMO and midsleep 
can be used as a marker for internal circadian alignment and 
may also be used for phase typing.34
Affective disorders such as major depressive disorder 
(MDD), bipolar disorder (BD), and seasonal affective 
disorder (SAD) are accompanied by circadian function dys-
regulations, including changes in biochemical (melatonin 
and cortisol profiles), actigraphic (sleep/wake patterns), 
and dimensional (chronotypes) circadian markers, which 
can occur during acute mood episodes as well as during 
euthymic periods.35–37
In fact, in addition to the classical monoaminergic hypoth-
eses that have been long proposed to explain the pathophysi-
ology of mood spectrum disorders, a strong association 
between circadian rhythms, dysregulation in melatonin 
secretion, and mood regulation has been suggested in the 
light of several preclinical and clinical findings.38–47
There is good evidence that melatonin contributes to the 
entrainment of the circadian rhythms of several biological 
functions, including activity/rest, sleep/wake, body tem-
perature, heart rate, liver and kidney function, and endo-
crine rhythms.45,48–50 Moreover, it is well documented that 
exogenous melatonin shows a good clinical response for 
reducing difficulties of falling asleep or improving symp-
toms associated with poorly coupled circadian rhythms, 
which may be present in the symptomatology of mood 
disorders.51,52 According to these findings, affective disorders 
caused by circadian dysfunction may be theoretically treat-
able by manipulating the circadian system using melatonin 
administration.46 However, there are contradictory data on 
its efficacy in the treatment of affective disorders.
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The present review aims to provide an overview of data 
published so far about the potential role of melatonin in 
affective disorders.
Methodology/search strategy
PubMed/Medline databases were searched by using the fol-
lowing sets of keywords: ([melatonin] AND [bipolar disorder 
OR major depression OR depression OR seasonal affective 
disorder OR affective disorder OR mania]). A selectively 
targeted literature review of English language studies was 
carried out. No time restrictions were placed on the electronic 
search covering the period up to January 2015. Secondary 
searches were performed using the reference list of identi-
fied papers/documents. To be included in the review, studies 
were required to investigate the circadian melatonin pattern 
(eg, its alterations) in the affective disorders (BD, MMD, or 
SAD). All studies not focusing on these specific topics were 
properly excluded, including animal studies; studies referring 
to melatonergic drugs; studies on population without a diag-
nosis of an affective disorder; studies on pregnant women, 
healthy subjects, or subjects affected with comorbid organic 
pathologies (eg, neuromuscular diseases); studies focusing 
on jet lag, sleep disorders, or bright light therapy. The search 
was performed independently by the authors. Data were 
compared and discrepancies were settled, if needed. Finally, 
data were then ranked in three macrocategories, eg, those 
pertaining to role of melatonin in MMD, those referring to 
BD, and, finally, those regarding SAD.
With the initial set of keywords, some 1,300 studies were 
identified. Of these, 448 were excluded because they were 
either focused on preclinical/animal research (328) or were not 
in English language (120); whilst 674 were did not meet the 
inclusion criteria. Out of the remaining 181 studies, 101 were 
excluded because they were duplicated or were not consistent 
with the aims of this review, leaving a total of 80 documents to 
be considered for inclusion in this review. A total of 49 studies 
were deemed of interest for MMD, of which 30 focused on 
circadian dysregulation in MDD (Table 1); 16 studies referred 
to BD, of which 8 referred to circadian dysregulation in BD 
(Table 2); and, finally, 15 focused on SAD, of which 9 focused 
on circadian dysregulation in SAD (Table 3).
The role of melatonin in major 
depressive disorder
Alteration of circadian rhythms in major depression, par-
ticularly unipolar depression, were first described more 
than 30 years ago.53–55 Several studies have later identified 
alterations in the melatonin secretory pattern in depression 
as well as in dysthymia; firstly, this suggests that, in MDD, 
the endogenous circadian pacemaker is set abnormally 
early (misaligned) with respect to the timing of sleep.56,57 
 However, subsequent studies have not consistently found 
that the endogenous circadian pacemaker is set either 
abnormally early (phase advanced) or late (phase delayed) 
in individuals with MDD58 and that there is a large range of 
circadian dysregulation. In particular, the most consistent 
findings have been lower nocturnal melatonin levels,53–55,59–72 
phase advance62,63,70,71,73–76 of melatonin onset77 or peak,62,63 
a delay in the peak,72,75,77–80 onset,63,81,82 or offset78 of mela-
tonin secretion, as well as a longer duration of aMT6s 
excretion.78
According to these findings, therapeutic strategies aimed 
at resynchronizing the circadian clock of depressed patients 
have been developed, such as sleep deprivation and light 
therapy,83–86 even though there are contradictory findings.87–90 
Furthermore, it was proposed to be a “low-melatonin syn-
drome”.62,91 However, further studies reported that only a 
subgroup of depressive patients had lower melatonin levels 
compared to healthy subjects.62,68,92,93 These patients showed 
an abnormal response to dexamethasone suppression test 
(DST).62,92,94,95
Conversely, other studies described increased levels 
in melatonin concentrations in depressive patients.79,81,96 
Therefore, it has been hypothesized that different melatonin 
patterns may reflect different subcategories of MDD64,82 and 
that melatonin levels may be also related to alterations in 
serotonin and norepinephrine levels.97,98
Furthermore, recent studies have found a relationship 
between severity of unipolar depression and circadian 
misalignment.80,82 In addition, clinical evidence that anti-
depressant drugs as well as mood stabilizers affect the 
rhythmicity of the melatonin secretion99–103 has pointed 
to the possibility of the involvement of melatonin in the 
pathophysiology of MDD.98,104–108
Finally, other studies have not demonstrated significant 
differences in melatonin pattern nor decrease/phase shift in 
MDD patients compared with healthy subjects,74,95,109 only 
reporting a nonsignificant trend toward higher melatonin lev-
els in MDD patients compared with healthy subjects.109,110
Although preclinical111,112 and some clinical113,114 data 
supported melatonin antidepressant potentialities in rodent 
models, melatonin seems to lack antidepressant activity in 
humans.115 In fact, the few studies administering melatonin to 
depressed patients found improvement of sleep disturbances, 
but no effect on depressive symptoms115,116 nor an  enhancing117 
effect of existing antidepressant therapies in patients with 
 
Ch
ro
no
Ph
ys
io
lo
gy
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
1.
97
.2
1.
39
 o
n 
20
-M
ar
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
ChronoPhysiology and Therapy 2015:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
68
De Berardis et al
Table 1 Melatonin circadian pattern in MDD: summary of the findings from literature
Author(s) Findings
Mendlewicz et al53 •  Significant lower nocturnal M levels in MDD
wetterberg54 •  Significant lower nocturnal M levels in MDD
Claustrat et al59 •  Significant lower nocturnal M levels in MDD
Parry and Newton61 •  Significant lower nocturnal M levels in MDD compared to HC
•  estrogen treatment increases M levels whilst progesterone antagonizes these effects
Beck-Friis et al62 •  Significant lower nocturnal M levels in MDD compared to HC
•  Phase advance of M onset in MDD
Nair et al63 •  Significant  lower nocturnal M levels in MDD compared to HC
•  Phase delay of M onset
Brown et al64 •  Significant lower nocturnal M levels in MDD (melancholic subgroup) compared to HC
Mcintyre et al65 •  Significant lower nocturnal M levels in MDD compared to HC
Frazer et al66 •  Significant lower nocturnal M levels in MDD compared to HC
Mcintyre et al67 •  Significant lower nocturnal M levels in MDD compared to HC
Fountoulakis et al68 •  Significant lower nocturnal M levels in melancholic depressed patients compared to atypical and undifferentiated depressed
Paparrigopoulos69 •  Significant lower nocturnal M levels in MDD compared to HC
wehr et al70 •  Phase advance of M onset in MDD
Buckley and  
Schatzberg71
•  Phase advance in MDD compared to HC
•  Significant lower nocturnal M levels in MDD compared to HC
Khaleghipour et al72 •  Significant lower nocturnal M levels in MDD compared to HC
•  Phase delay of M peak in MDD compared to HC
voderholzer et al74 •  No difference between night time levels of M in MDD and HC
•  Phase advance of M onset in MDD
Crasson et al75 •  Significant lower nocturnal M levels in MDD compared to HC
•  Phase-shifted M secretion in MDD compared to HC
•  Urinary aMT6s concentrations enhanced in the morning compared to night time levels in MDD (compared to HC)
wehr and Goodwin76 •  Phase advance of M onset in MDD
Tuunainen et al78 •  Correlation between delayed offset of aMT6s excretion and MDD
•  Phase delay of M offset in MDD
Rubin et al77 •  Significant higher nocturnal M levels in MDD compared to HC
emens et al79 •  Phase delay of M onset is correlated with depression severity
Parry et al80 •  increased M secretion into the morning in MDD compared to HC
•  Phase delay in MDD compared to HC
Hasler et al81 •  No significant group differences in the PAD between MDD and HC
•  A greater heterogeneity in PAD among MDD patients
Robillard et al82 •  No significant group difference in the PAD between MDD and BD
•  Phase delay of M onset in young people with MDD and BD
Rahman et al91 •  Low M secretion may desynchronize endogenous rhythms allowing subsyndromal MDD
Beck-Friis et al92 •  Significant lower nocturnal M levels in MDD and BD compared to HC
Carvalho et al94 •  No significant differences in M secretion between MDD and HC
•  No decrease nor a phase shift in MDD
Sekula et al110 •  No difference between nighttime levels of M in MDD and HC
•  Only a trend toward higher M levels in MDD
Shafii et al96 •  Significant higher nocturnal M levels in MDD compared to HC
Thompson et al109 •  No difference between night-time levels of M in MDD and HC
•  Only a nonsignificant trend toward higher M levels in MDD
Abbreviations: PAD, phase angle difference; MDD, major depressive disorder; BD, bipolar disorder; HC, healthy controls; M, melatonin; aMT6s, 6-sulfatoxymelatonin.
treatment-resistant depression.118 To date, according to a recent 
metaanalysis,119 there is no clear evidence of a therapeutic or 
prophylactic effect of melatonin in MDD.
The role of melatonin in bipolar 
disorder
Chronobiological models have contributed to a better under-
standing of the pathophysiology of BD. Circadian function 
dysregulations, changes in the timing, and phase position are 
associated with BD, including melatonin secretion and sleep/
wake patterns.86,98,119 In particular, it has been noted that in 
manic patients phase alterations such as phase advance in 
melatonin levels120,121 and delayed peak melatonin secretion 
are accompanied by lower melatonin levels.86
Although melatonin has proved to be a reliable marker of 
circadian phase, few studies have focused on this measure in 
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Table 3 Melatonin circadian pattern in SAD: summary of the 
findings from literature
Author(s) Findings
Lewy et al34 •  Most SAD are phase-delayed
•  A SAD subgroup is phase-advanced
Lewy et al141 •  Phase delay of M onset during the winter in SAD
wehr et al142 •  Phase delay of M onset during the winter rather 
than summer in SAD
•  Phase delay of M offset in SAD compared to HC
Káradóttir and  
Axelsson143
•  Higher M levels in SAD compared to HC
Danilenko et al144 •  Higher M levels during winter in SAD compared 
to HC
Lewy et al148 •  Phase delay of M onset during the winter in SAD
Terman et al149 •  Phase delay of M onset in SAD
Dahl et al150 •  Phase delay of M onset in SAD compared to HC
Checkley et al151 •  No significant differences in circadian rhythms 
between SAD and HC
Abbreviations: SAD, seasonal affective disorder; M, melatonin; HC, healthy 
controls.
Table 2 Melatonin circadian pattern in BD: summary of the 
findings from literature
Author(s) Findings
Robillard  
et al82
•  No significant group difference in the PAD between 
MDD and BD
•  Longer phase delay of M onset in BD compared to MDD
Lam et al87 •  Significant lower nocturnal M levels in BD compared  
to HC and MDD
Beck-Friis  
et al92
•  Significant lower nocturnal M levels in MDD and BD 
compared to HC
Lewy  
et al120
•  Significant lower nocturnal M levels in BD during 
depressed phase
•  Significant higher nocturnal M levels in BD during 
manic phase
•  Phase advance of M onset in BD
Kennedy  
et al121
•  Significant lower nocturnal M levels in BD during 
depressed phase
•  Significant higher nocturnal M levels in BD during 
manic phase
•  Phase advance of M onset in BD
Kennedy  
et al122
•  No significant differences in M secretion among 
several BD states
•  Significant lower nocturnal M levels in BD compared 
to HC
•  No significant differences in aMT6s levels between BD 
and HC
Souetre  
et al177
•  Significant lower nocturnal M levels in BD during 
depressed phase
•  Significant higher nocturnal M levels in BD during 
manic phase
•  Restoration of M levels during the remission of BD
Lewys  
et al123
•  Significant lower nocturnal M levels in BD during 
depressed phase
•  Significant higher nocturnal M levels in BD during 
manic phase
Abbreviations: PAD, phase angle difference; MDD, major depressive disorder; 
BD, bipolar disorder; M, melatonin; HC, healthy controls.
BD and have yielded contradictory findings. Some studies 
reported phase disturbances82,86,120,121 in the melatonin secre-
tion in BD whilst others reported no phase variations.122 
Subjects affected by BD have demonstrated significantly 
lower peak nocturnal melatonin levels when compared to 
healthy controls86,87,92,122 and unipolar depressive patients.87,122 
Furthermore, both euthymic and acutely ill bipolar patients 
have also demonstrated a hypersensitive pineal response to 
ocular light exposure when compared to controls.57,89 Some 
studies, which specifically evaluated patients affected with 
BD, reported a reduction in melatonin secretion during the 
depressed phase and an increase in the manic phase of the 
illness whilst a restoration during the remission of symp-
tomatology.120,121,123 These findings suggested that melatonin 
levels in BD might be more a “trait marker” rather than a 
“state marker”.122
It remains unclear whether these findings indicate a pri-
mary dysfunction of the circadian timing system or whether 
they may be secondary to sleep disturbances, a prominent 
characteristic in BD.
Sleep disturbance is a hallmark of BD. Sleep disturbances 
have been associated with a worse course of illness,124,125 
increased symptom severity, and impairments in function-
ing and quality of life.124–126 In fact, patients affected with 
BD exhibit marked reduction in sleep during the night 
prior to switching from depressive to manic phase of the 
illness.76,127–129 A case report evaluation efficacy of melatonin 
administration in a young refractory BD patient showed 
relief from insomnia and manic episode.130 An open-label 
study reported that melatonin administration was associated 
with increased sleep duration as well as decrease in manic 
 symptoms.129 A recent prospective naturalistic study reported 
sleep and mood improvement after administration of exog-
enous melatonin.131 Melatonin did not have a beneficial effect 
in another study conducted on bipolar patients.132
The role of melatonin  
in seasonal affective disorder  
or winter depression
The role of melatonin in the seasonal changes in physiol-
ogy and behavior of various photoperiodic species has been 
extensively documented.89 In fact, the seasonal alterations 
of the natural photoperiod at high latitudes have a repercus-
sion on melatonin secretion,133 and the melatonin rhythm is 
delayed during winter compared with the summer.134 Some 
studies reported that these alterations in melatonin secretion 
were also found in healthy subjects.135–138
SAD or winter depression affects upward of 10% of the 
population at temperate latitudes.139 It is  characterized by 
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Table 4 Current melatonergic drugs on the market or under evaluation
Melatonergic drug Trade  
names
Approval Pharmacological 
actions
Chronobiotic 
effects
Clinical effects
Sleep Mood
Agomelatine (Servier) valdoxan® 
Melitor® 
Thymanax®
eMA  
(2009)
MT1/MT2  
nonselective agonist 
5-HT-2C antagonist 
5-HT-2B antagonist
Phase advance and  
entrains circadian  
system
Significant benefits in MDD Significant  
benefits in  
MDD and SAD
Ramelteon (Takeda  
Pharmaceutical Company)
Rozerem® FDA  
(2005)
MT1/MT2  
nonselective agonist
Phase advance Significant benefits  
in insomnia
N/A
Tasimelteon (VEC-162;  
Vanda Pharmaceuticals)
Hetlioz® FDA  
(2014)
MT1/MT2  
nonselective agonist
Phase advance and  
phase delay
Significant benefits in non- 
24-hour sleep–wake disorder
N/A
TIK-301 (PD-6735,  
LY-156, 735; Tikvah  
Pharmaceuticals)
– – MT1/MT2  
nonselective agonist
Promotes phase 
advance
Significant benefits in  
insomnia
N/A
UCM765 – – MT2 selective  
partial agonist
N/A N/A N/A
iiK7 – – MT1/MT2 full  
agonist
N/A N/A N/A
UCM793 – – MT1/MT2  
nonselective agonist
N/A N/A N/A
UCM924 – – MT2 selective  
partial agonist
N/A N/A N/A
Neu-P11 (Neurim  
Pharmaceuticals Ltd)
– – MT1/MT2  
nonselective agonist
N/A N/A N/A
Abbreviations: eMA, european Medicines Agency; MT, melatonin receptor; MDD, major depressive disorder; SAD, seasonal affective disorder; N/A, not available; FDA, 
US Food and Drug Administration.
recurrent depressive episodes during the short photoperiod 
(usually, fall/winter months) and euthymia during spring/ 
summer periods. Individuals with SAD are  negatively affected 
by the shorter days and later sunrise of the winter months and 
develop a syndrome characterized by  carbohydrate craving, 
lethargy, fatigue, and sadness.36
Changes in duration and/or phase of melatonin secretion 
during this period (the so called “phase shift hypothesis”)140 
were hypothesized to play a role in the pathogenesis of SAD 
and prompted its treatment with phototherapy.141 In patients 
affected with SAD, the most prominent marker of seasonal 
variations may be represented by the change in the melatonin 
offset.142 In fact, it seems that these patients generate a biologi-
cal signal indicative of the seasonal change, like photoperiodic 
animals do.142,143 In addition, several studies have documented 
higher daytime melatonin levels during the winter season in 
patients affected with SAD compared to healthy controls142–144 
and phase delay of circadian rhythms during the winter 
months.141,142,145–150 However, other studies underlined no sig-
nificant differences in circadian rhythms between SAD patients 
compared with the healthy controls evaluated.151
Although phototherapy is an effective treatment of SAD, 
because it induces a phase advancing141,144,149,150 of circadian 
rhythms by correcting the PAD between circadian and sleep–
wake schedules, the beneficial effect of this treatment does not 
seem to be supported by changes in melatonin.121,143,145,146,152
Studies focusing on efficacy of melatonin administration 
in SAD patients showed contradictory findings.153 In fact, 
although some studies reported a significant improvement of 
mood symptomatology;148,154 no significant differences were 
demonstrated after administrating exogenous melatonin com-
pared with the placebo group.155,156 However, the phase shift 
hypothesis supports its efficacy in the treatment of seasonal 
circadian dysregulation in SAD patients, due to its capabil-
ity to cause phase advances (when taken during evening) or 
phase delays (when taken during morning).34,140
Current melatonergic  
drugs on the market
In the last years, advances in medicinal chemistry led to 
the discovery of compounds that are specific and selective 
agonists and antagonists for melatonin receptors. Amongst 
them, some melatonergic drugs are on the market and are 
currently used in the clinical practice whilst others are also 
under evaluation (Table 4).157–175
For a more comprehensive review see Carocci et al.176
Discussion and summary
The present narrative review aimed to summarize available 
evidence on circadian melatonin dysregulation in affective 
disorders. However, the findings provided here include a 
large number of contradictory data. Most of the studies 
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retrieved present a greater heterogeneity in sample number 
and characteristics and in inclusion and exclusion criteria. 
For example, the extreme variability in melatonin pattern in 
MDD may suggest, both, the existence of different subgroups 
of depressive patients (eg, with different degrees of severity 
or a seasonal vulnerability) and an inaccurate initial selection 
of MDD patients (eg, an inclusion of subsyndromal BD or 
SAD patients). In addition, it could be argued that most data 
may be influenced by the choice of the age of the sample. In 
fact, a different circadian alignment according to the age has 
been reported. Another limitation may be represented by the 
small sample size used in most studies analyzed here, which 
may limit the generalizability of data.
SAD and mood disturbances (MDD and BD) caused 
by circadian malfunction are theoretically treatable by 
manipulating the circadian system using chronobiotic drugs, 
chronotherapy, or bright light therapy. There is no doubt 
that melatonin has chronobiotic properties as well as the 
ability to induce transient sleepiness or sleep. However, 
very few and contradictory evidence exist about its role in 
mood disorders and its potentiality in the treatment of these 
disorders. In fact, although melatonin appears to be well 
tolerated and is an effective treatment for a number of sleep 
disorders related to circadian rhythm disturbance, there is no 
conclusive confirmation about its efficacy in the treatment 
of mood disorders. However, due to the well-documented 
alterations in circadian rhythms and in melatonin secretion 
in mood disorders, more effective melatonin analogs (eg, 
agomelatine, tasimelteon, etc) have been developed and 
studied in order to obtain a reliable and effective drug for 
the treatment of mood disorders.
Further studies are necessary in order to better character-
ize the effect of exogenous melatonin and novel melatoner-
gic drugs on the circadian system of MDD, BD, and SAD 
patients.
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